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Abstract
Mounting evidence suggests that there is frequently considerable variation in the risk of the outcome of interest in
clinical trial populations. These differences in risk will often cause clinically important heterogeneity in treatment
effects (HTE) across the trial population, such that the balance between treatment risks and benefits may differ
substantially between large identifiable patient subgroups; the “average” benefit observed in the summary result
may even be non-representative of the treatment effect for a typical patient in the trial. Conventional subgroup
analyses, which examine whether specific patient characteristics modify the effects of treatment, are usually unable
to detect even large variations in treatment benefit (and harm) across risk groups because they do not account for
the fact that patients have multiple characteristics simultaneously that affect the likelihood of treatment benefit.
Based upon recent evidence on optimal statistical approaches to assessing HTE, we propose a framework that
prioritizes the analysis and reporting of multivariate risk-based HTE and suggests that other subgroup analyses
should be explicitly labeled either as primary subgroup analyses (well-motivated by prior evidence and intended to
produce clinically actionable results) or secondary (exploratory) subgroup analyses (performed to inform future
research). A standardized and transparent approach to HTE assessment and reporting could substantially improve
clinical trial utility and interpretability.
Introduction
When the Scottish epidemiologist Archie Cochrane sug-
gested that clinical practice should principally be guided
by rigorously designed evaluations, in particular rando-
mized clinical trials (RCTs), the reaction of the medical
profession was largely negative. Critics suggested that
relying on impersonal statistically-derived “evidence”
based on averages to determine clinical decision-making
was antithetical to the practice of medicine, which
should rather be based on a physician’s expertise, acu-
men and clinical experience, and on knowing the indivi-
dual patient and considering what is best for each
person given their individual circumstances and needs
[1-3].
Although “evidence-based medicine” has become the
dominant paradigm for shaping clinical recommenda-
tions and guidelines, recent work demonstrates that
many clinicians’ initial concerns about “evidence-based
medicine” come from the very real incongruence
between the overall effects of a treatment in a study
population (the summary result of a clinical trial) and
deciding what treatment is best for an individual patient
given their specific condition, needs and desires (the
task of the good clinician) [4-7]. The answer, however,
is not to accept clinician or expert opinion as a replace-
ment for scientific evidence for estimating a treatment’s
efficacy and safety, but to better understand how the
effectiveness and safety of a treatment varies across the
patient population (referred to as heterogeneity of treat-
ment effect [HTE]) so as to make optimal decisions for
each patient.
The conventional method of examining whether treat-
ment effects vary in a trial population is to divide
patients into subgroups based on potentially influential
characteristics. The main problem with the conventional
approach is that there are too many characteristics that
can potentially influence treatment effect. This leads to
myriad subgroup analyses which are typically both
underpowered and vulnerable to spurious false positive
results due to multiple comparisons. For these reasons,
subgroup analyses are usually “exploratory” and rarely
actionable, leaving the clinician to assume that all
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any medium, provided the original work is properly cited.patients meeting trial inclusion criteria should be simi-
larly treated.
Herein, we propose a framework that directly
addresses the problem of multiplicity in two ways. First,
our framework prioritizes the analysis and reporting of
multivariate risk-based HTE, over conventional “one-
variable-at-a-time” subgroup analysis. This recommen-
dation is based on an understanding that HTE emerges
from just a few fundamental risk dimensions. These
dimensions–which include the risk of the primary study
outcome (the main focus of our proposed approach),
competing risk, the risk of treatment-related harm and
direct treatment-effect modification [5-8]–can often be
summarized using multivariate prediction models,
greatly simplifying subgroup analyses and substantially
improving statistical power[9]. Second, this framework
proposes that other subgroup analyses should be expli-
citly labeled either as primary subgroup analyses (well-
motivated by prior evidence and intended to produce
clinically actionable results), which should be few in
number and appropriately adjusted for multiple compar-
isons, or secondary (exploratory) subgroup analyses
(performed to inform future research).
Why the overall result from a clinical trial is sometimes
unreliable for guiding clinical practice
When considering whether a patient is likely to benefit
from a therapy, the most relevant measure of treatment
effect is the absolute risk reduction (ARR) (see Appen-
dix 1) of a treatment (or its reciprocal, the number
needed to treat [NNT], [see Appendix 1]) [10,11]. It is
well known that a study’s overall ARR or NNT will
often not reflect a treatment’st r u eA R Rf o rm a n yp e o -
ple in the trial, since a 25% relative risk reduction (RRR)
(see Appendix 1) in high risk patients produces much
more benefit than it does in low-risk patients (resulting
in substantial HTE). For example, Table 1 shows results
for a hypothetical treatment that reduces all study sub-
jects’ risk by 25%. This results in the overall NNT of 50
greatly underestimating the benefits for high-risk sub-
jects (NNT = 20) and greatly over-estimating the bene-
fits for the typical patient (NNT = 100).
Indeed, because a minority of high-risk patients may
account for most trial adverse outcomes and because
even a small degree of treatment-related harm can nul-
lify or outweigh benefits in low risk patients, it does not
take extreme assumptions to produce scenarios in which
almost all individuals [6,12,13] in the trial have an ARR
that is substantially lower than that suggested by the
summary results reported in the trial. For example,
Table 2 shows results that would emerge if the treat-
ment reduces disease-related risk by 25% (just like in
T a b l e1 )b u tn o wa l s oc a r r i e sa2i n1 0 0 0r i s ko fas e r -
ious treatment-related harm (due to adverse events or
major side-effects). In Scenario #1, the clinical trial’s
overall result suggests that the treatment has a moderate
benefit (RRR = 12.5% and NNT = 100), despite the fact
that 75% of study subjects received absolutely no net
benefit (i.e. treatment-related harm equals treatment
benefit). In Scenario #2, we see that if the difference
between outcome risks of low vs. high risk patients is
increased (i.e. risk strata more dissimilar in risk), the
summary results can still suggest an overall benefit of
treatment even though the treatment risks out-weigh
treatment benefits for 75% of study subjects (Table 2).
While these examples illustrate cases in which the
absence of risk-based analysis will result in harmful (or
merely wasteful) over-treatment, under certain circum-
stances the opposite may also be the case; a treatment’s
effect may be null overall, even though it provides sub-
stantial benefit in a patient subgroup (typically at high
risk for the outcome of interest or at especially low risk
of treatment-related harm) [14,15].
Why risk stratified analyses should be performed
whenever feasible
Although the degree of heterogeneity in risk shown in
Tables 1 and 2 may seem extreme, such variability in
Table 1 How summary results of clinical trials can be misleading even when everyone gets the same relative risk
reduction
Assumption: Treatment reduces baseline risk by 25% without any treatment related harm
Control Event
Rate*
(CER, %)
Experimental Event
Rate
(EER, %)
Relative Risk Reduction
(RRR)
Absolute Risk
Reduction
(ARR)
Number Needed to Treat
(NNT)
(% of study
population)
Overall result (100%) 8 6 0.25 0.02 50
Average risk subjects
(75%)
4 3 0.25 0.01 100
High risk subjects
(25%)
20 15 0.25 0.05 20
* See Appendix 1
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assessed using a multivariable prediction tool. It has
been documented that outcome rates in the highest risk
quartile (the 25% of study subjects with the highest pre-
dicted risk) in large clinical trials is often 5-20 times
higher than in the lowest risk quartile [5,16-20]. While
the degree of risk heterogeneity may vary across medical
domains, multiple independent risk factors exist for vir-
tually any clinical outcome that would be the target of a
therapeutic trial, and therefore, substantial risk heteroge-
neity should be common. In turn, the presence of risk
heterogeneity mathematically implies the presence of
HTE, on the absolute risk scale, regardless of whether
there is also HTE on the relative risk scale.
Recent research has demonstrated that, even when
there are large and clinically important differences in
treatment effects across risk groups, conventional sub-
group analyses (which assess HTE “one-variable-at-a-
time”) are inadequate to detect these differences across
risk subgroups because they do not account for the fact
that patients have multiple variables that determine risk
simultaneously [6,9,21-24]. Instead, they examine treat-
ment effect differences based on groups differing on
only a single variable, falsely determining a “consistency
of treatment effect” across subgroups simply because the
groups compared are more similar than dissimilar.
Additionally, because conventional subgroup analyses
involve multiple comparisons and involve splitting the
overall sample to smaller sub-samples, they are both
under-powered for detecting genuine subgroup effects
(prone to false-negatives), and even more commonly
they are prone to false positive findings [25-31]. Clinical
trials, so analyzed, can thus result in treatment
recommendations and guidelines that promote substan-
tial over- and under-treatment.
There are better alternatives to one-variable-at-a-time
subgroup analyses. Multivariable subgroup analysis is
theoretically possible, and has been shown to be poten-
tially useful[5], but statistical power is usually inade-
quate in anything other than pooled analyses of data
from multiple trials. Risk-based analyses using multivari-
able risk prediction tools are more often feasible and
have a lower risk of false positive findings than single
variable subgroup analysis, when employed as a single
pre-specified analysis that avoids the multiplicity of
comparisons inherent in testing each sub-grouping vari-
able separately[9]. Moreover, such an analysis will often
have more optimal statistical power, as it compares
patients that differ in multiple important characteristics
simultaneously. Otherwise undetected yet clinically
meaningful differences in relative treatment benefit have
been demonstrated in many areas where multivariate
risk-based approaches have been applied, most particu-
larly in the areas of cardiovascular and cerebrovascular
disease, but others as well (Table 3).
A proposal for reporting clinical trials to provide more
information on clinically important heterogeneity in
treatment effects (HTE)
Several recent papers have addressed important consid-
erations when conducting and interpreting subgroup
analyses [5-7,9,14,22,27,30,32-40], but did not recom-
mend a specific framework for reporting HTE and did
not discuss how to deal with multivariable risk analyses.
Only a few previous papers have addressed multivariable
risk analyses. Herein, we propose some practical
Table 2 How summary results can obscure situations where the typical patient receives no benefit or harm
Assumption: Treatment reduces baseline risk by 25% but with a cost of 2 serious treatment-related adverse events per 1,000 patients per year
Control Event
Rate
(CER, %)
Experimental Event
Rate
(EER, %)
Relative Risk Reduction
(RRR)
Absolute Risk
Reduction
(ARR)
Number Needed to Treat
(NNT)
(% of study
population)
Results over 5 years
Scenario #1
Overall result (100%) 8 7 0.125 0.01 100
Average risk subjects
(75%)
44 0 0 ∞
High risk subjects
(25%)
20 16 0.2 0.04 20
Scenario #2
Overall result (100%) 9 7.75 0.14 0.0125 80
Average risk subjects
(75%)
2 2.5 -0.25† -0.005† -200
High risk subjects
(25%)
30 23.5 0.22 0.065 15
† The minus sign denotes that treatment had net harm, rather than benefit.
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performed and presented (summarized in Appendix 2).
While this framework has not been subjected to a for-
mal consensus building process involving a broad sam-
ple of stakeholders and is therefore provisional, the
approach is a synthesis of ideas and contributions made
by many investigators [4-7,9,14,16,17,27,41], and is pro-
posed to provide a considered basis for subsequent dis-
cussion, revision, and refinement.
Recommendation #1: Evaluate and report on the
distribution of baseline risk in the overall study
population and in the separate treatment arms of the
study by using a risk prediction tool
Although its importance was highlighted over a decade
ago[12], reporting the distribution of baseline risk (see
Appendix 1) is rarely done. Therefore, it is generally
impossible to assess the degree of baseline risk heteroge-
neity in most published clinical trials, since risk hetero-
geneity cannot be determined when each risk factor’s
prevalence is listed individually.
The precise approach for presentation is not impor-
tant, as long as it allows the reader to understand the
distribution of predicted baseline risk (or the risk score
o far i s ki n d e x )i nt h es t u d yp o p u l a t i o n .“Table 1“ of a
clinical trial report (which conventionally includes
patient attributes for those in the different study arms)
should include, at minimum, the population mean (+
SD) and median predicted baseline risk (or risk score),
and additional information on the population distribu-
tion if there is substantial skew in subject risk (such as
quartiles/percentiles, a histogram or a box plot) (see
Table 4). If the study includes a largely homogeneous
population with regard to overall risk, the reader will
know that generalizing the study results to those with
substantially different risk would be speculative. If there
is substantial heterogeneity in the study population,
then reviewers will know that risk stratified analysis is
particularly important.
Finally, including this information in “Table 1“ of a
clinical trial allows the reader to assess whether there
are important baseline differences between treatment
Table 3 Examples of Clinically Important Risk-based Heterogeneity of Treatment Effect
Clinical Condition Treatments Findings
Symptomatic carotid
stenosis
Carotid endarterectomy (CEA) While overall results showed CEA to reduce stroke risk in patients with severe
stenosis, risk-benefit stratification demonstrated that benefit is limited to those
with high risk features, but without risks factors for perioperative complications
[21].
Non-valvular atrial
fibrillation (AF)
Anticoagulation for primary
prevention of stroke
While warfarin prevents stroke in patients with AF compared to aspirin, patients
without risk factors for stroke do not benefit incrementally[49,50].
Coronary artery disease
(CAD)
Coronary artery bypass grafting
(CABG)
Early coronary artery bypass grafting reduces total mortality compared to medical
therapy in medium and high risk patients, while low risk patients have a non-
significant trend toward increased mortality[64].
Primary prevention of
coronary artery disease
Lipid lowering Statin therapy reduced risk of myocardial infarction or death, but low risk patients
are highly unlikely to benefit despite hyperlipidemia[65].
Acute coronary
syndromes (ACS)
Early invasive (versus conservative)
strategy
Enoxaparin (versus unfractionated
heparin)
Tirofiban (versus placebo)
These therapies reduce the risk of myocardial infarction or death in high risk but
not in low risk patients[46-48,66,67]. The risks of bleeding with intensive
antithrombotic regimens outweigh benefits in low risk patient. Risk stratification
has become central to the management of ACS[68].
ST-Elevation acute
myocardial infarction
tPA (versus streptokinase)
Percutaneous coronary intervention
[PCI] (versus thrombolytic therapy)
tPA improves mortality in high risk patients compared to streptokinase, but not
in low risk patients. When low risk patients have an excess of risk factors for
bleeding, risks of therapy may outweigh benefits[17,55].
Mortality benefits of PCI are limited to only a relatively limited high risk subgroup
[69,70].
Severe sepsis Drotrecogin alfa (activated protein C) While the pivotal phase III trial demonstrated a significant mortality reduction
overall, this was found to be limited only to the half of patients with a high
baseline mortality risk. Lower risk patients were exposed to bleeding risks,
without a mortality benefit [68,71,72].
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ferences in overall risk for the study’s main outcome). It
is common to note multiple modest deviations between
treatment arms when baseline patient factors are listed
one at a time. These differences typically have little
influence on trial results, particularly when they com-
bine so as to cancel each other out. However, similar
differences in overall baseline risk may influence the
trial result, such that comparing the risk distribution
between the treatment groups using a composite risk
model can be informative and facilitate risk adjustment.
Recommendation #2: Report how relative and absolute
risk reduction varies by baseline risk, using a
multivariable prediction tool
There are two fundamental reasons why all clinical trials
should attempt to assess how net treatment benefit and
safety vary as a function of predicted untreated risk: 1)
It allows us to understand how absolute risk reduction
varies across the study population even when relative
risk reduction is constant (see Table 1); and 2) net rela-
tive risk reduction may not be constant across risk
groups, particularly if there is even a small amount of
treatment-related harm (see Table 2). For major clinical
trials (those that assess a treatment’s effect on mortality
and major morbidity), it is usually possible to perform
risk-based analysis of HTE using an externally developed
tool, since prediction tools to estimate overall risk have
been developed for most major conditions and their
complications (including cardiac, cancer, stroke, renal
failure, ICU and hospital morality, etc [see Additional
file 1]). Testing risk-based HTE using internally-
developed models (based on a blinded regression analy-
sis of the data using all treatment arms) may be useful
when such models do not exist. However, when avail-
able, we favor the use of an externally developed predic-
tion model since over-fitting can potentially exaggerate
the degree of risk heterogeneity.
In reporting risk stratified results, readers should be
provided with the information needed to easily deter-
mine the amount of variation in ARR/NNT and RRR.
An approach to presenting these results to a general
readership is shown in Table 5. How statistical testing
for HTE should be addressed, including for multivari-
able risk-stratified analyses, is discussed below (Recom-
mendation #5).
Recommendation #3: Additional primary subgroup
analysis for single variables should be pre-specified and
limited to patient attributes with strong a priori
pathophysiological or empirical justification
Here we define primary subgroup analysis as those
subgroup comparisons that are well justified (hypoth-
esis-testing, not hypothesis-generating) so as to yield
potentially actionable results appropriate for guiding
clinical care. Therefore, all primary subgroup compari-
sons must be fully specified and justified a priori.
The number of comparisons made in the primary sub-
group analysis should be kept small in number to mini-
mize false positive results, since each additional
subgroup comparison decreases the usefulness of the
other primary subgroup analyses and should therefore
exact a statistical penalty (see recommendation #5).
Often, no single variable subgroup analysis (such as by
age, by sex, by race, etc.) will be indicated as part of the
primary subgroup analysis. Rather, these should gener-
ally be conducted as exploratory (secondary) analyses
(see recommendation #4), unless: 1) there exists pre-
vious empirical evidence from observational studies or
exploratory subgroup analyses in prior clinical trials; or
2) there are highly compelling reasons to believe the
patient attribute is likely to importantly influence the
relative treatment effect (such as time to treatment with
time-sensitive therapies or biomarkers that are strong
candidates to be specific targets of therapy [e.g. estrogen
receptor positivity in breast cancer]).
Prespecification of primary subgroups should include
explicit definitions and categories of the subgroup vari-
ables, including cut-off thresholds for continuous or
ordinal variables where these are used, and the antici-
pated direction of the effect modification. While it is
ideal that analyses should be pre-specified at the time of
trial initiation [22,27], it is most important that all pri-
mary subgroup analyses be pre-specified prior to exami-
nation of the data to ensure that analyses are not biased
by multiple comparisons, including post-hoc changes in
variable construction to better “fit the data”.B yc o n -
ducting primary subgroup analysis that are few in
Table 4 Presenting the distribution of baseline risk in
clinical trials
Frequency
(%)
Predicted Risk* Control
(N = 200)
Intervention
(N = 200)
Total
(N = 400)
< 5% 69 (34.5%) 69 (34.5%) 138 (34.5%)
5%-15% 90 (45.0%) 95 (47.5%) 185 (46.3%)
> 15% 41 (20.5%) 36 (18.0%) 77 (19.3%)
Mean + SD 9.2 (8.6) 9.8 (9.3) 9.5 (9.0)
Median (Q1 -Q 3) 6.4 (3.7-10.9) 7.0 (3.6-11.9) 6.8 (3.6-11.3)
EQuRR** - - 12.4
* Presenting results so that reader can easily observe whether the relative risk
reduction or number needed to treat vary based upon the individuals
baseline risk of the outcome. In this example, the risk model is expressed as
predicted risk (%). However, presentation of results stratified according to a
risk score would be similarly informative.
** Extreme quartile risk ratio, the predicted risk in the highest risk quartile
divided by the risk in the lower risk quartile
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statistically robust (see recommendation #5), examina-
tions of HTE can produce strong and actionable evi-
dence regarding which patients are most likely to
benefit from treatment.
Recommendation #4: Secondary (exploratory) subgroup
analyses should be clearly distinguished from primary
subgroup comparisons
Although we propose making a clear distinction
between primary and secondary subgroup analyses, it
would be a mistake to forgo secondary analyses. Second-
ary analyses can explore evidence of unexpected rela-
tionships between individual patient attributes and
treatment effects. Although exploratory analyses are an
important part of scientific discovery, it is critically
important to understand that such analyses are mainly
appropriate for hypotheses generation, which can then
be tested (and usually disproved) in future studies.
Although medical journals may be reluctant to report
“exploratory” analyses, it would be quite easy to routi-
nely include secondary subgroup analyses in an electro-
nic appendix to be published online with the main
results of a clinical trial, making them available to the
scientific community and for future meta-analyses while
keeping them distinct from the primary results.
Recommendation # 5 All analyses conducted must be
reported and statistical testing of HTE should be done
using appropriate methods (such as interaction terms)
and avoiding overinterpretation
Reporting must include results for all subgroup ana-
lyses, including multivariate-risk, primary and secondary
subgroup analyses, and the paper must state that
the primary subgroup analyses conducted were pre-
specified. Because statistically significant benefit is likely
to be absent in small subgroups, the correct analysis is
not to test the significance of the treatment effect in
one subgroup or another, but whether the effect differed
significantly between subgroups. Work by Brookes et al
suggests that the most statistically robust approach to
assessing HTE is using interaction terms in regression
models [22,23]. Further, they found that testing continu-
ous variables (such as baseline LDL level) is substantially
more statistically powerful than testing categorical vari-
ables (such as baseline LDL < 100 vs. 100-145 vs > 145).
Therefore, unless there is reason to believe that an effect
is non-linear, HTE of continuous effects should be
tested using the full power of the continuous variable,
although categorical results can be shown for simplified
presentation in the results section (see Table 5).
Where formal statistical testing fails to detect hetero-
geneity on the relative risk scale, the conservative
assumption of a constant relative risk reduction across
all risk groups may generally apply, especially if the
study is large enough so that the test for interaction is
adequately-powered. One should beware of the remain-
ing possibility of false-negatives (as well as false-
positives), especially in underpowered settings.
Therefore interpretation of interaction effects should be
cautious and viewed also in the context of additional
prior/external evidence.
Results of subgroup analyses should be presented so
that ARR/NNT as well as RRR can be assessed across
risk categories or other subgroups. For instances where
multiple single-variable subgroup analyses are performed
as part of the primary subgroup analysis, the significance
threshold should be adjusted for multiple testing[42,43].
Caveats and Future Work
Ideally, a continually updated registry containing
easily-applicable, well-accepted, well-validated predic-
tion tools for all the primary clinical outcomes used in
trials for all major medical conditions would be avail-
able. We recognize that this is not currently the case
and that the state of the predictive modeling literature
is far from this ideal even for fields that have a long
tradition in predictive modeling[44,45]. However, while
Table 5 Presenting results showing heterogeneity in treatment effect (HTE)*
Weighted
Event Rate
Relative Risk Reduction Number Needed to Treat
Predicted Risk* Control Intervention (95% CI)
< 5% 15/428 (3.5%) 17/431 (3.9%) -13% (-122%, 43%))** -250**
5%-15% 66/581 (11.4%) 48/580 (8.3%) 27% (-4%, 49%) 32
> 15% 66/310 (21.3%) 38/307 (12.4%) 42% (16%, 60%) 11
Overall 147/1319 (11.1%) 103/1318 (7.8%) 30% (11%, 45%) 30
* Although the predicted baseline risk can be shown in categories, the statistical testing of HTE should usually be based upon the full continuous variable. If
standard predicted risk categories have been previously proposed in the validated prediction model, this should be stated, referenced appropriately, and clarified
why these risk categories make sense (e.g. thresholds for deciding on whether some standard treatment is indicated, uncertain, or not indicated).
** Negative sign denotes net harm, denoting relative risk increase or number need to harm.
Kent et al. Trials 2010, 11:85
http://www.trialsjournal.com/content/11/1/85
Page 6 of 10there is not a well-accepted and validated prediction
tool appropriate for every condition, it is important to
understand that testing for evidence for HTE using a
risk-stratified analysis is a much easier task than deter-
mining how risk-stratification should be used in clini-
cal practice. Recent research has demonstrated that a
risk prediction tool of even moderate predictive power
can typically provide adequate statistical power for
answering the scientific question of whether there is
evidence that the RRR of treatment varies significantly
as a function of baseline risk [9]. It has been shown
that even a relatively mediocre prediction tool
(AUROC .6 to .65) can substantially improve statistical
power over that achieved by examining even strong
single risk factors one at a time to test for the pre-
sence of risk-based HTE [9]. Indeed, several commonly
used scores, such as the Thrombolysis in Myocardial
Infarction (TIMI) risk score (for acute coronary syn-
drome) and CHADS2 score (for non-valvular atrial
fibrillation), have discriminatory power in this range
but have nevertheless proved useful in the detection of
risk-based HTE (see Table 3) [46-50].
Moreover, for many fields, it is likely that the widely-
accepted predictive models will not be stable but will
continuously improve with the addition of new informa-
tive predictors (e.g. previously unrecognized genetic risk
factors). One may conceive the possibility of re-analyses
of the results of clinical trials using more informative
prediction models if and when such additional informa-
tion has been collected. Such re-analyses need to follow
equally robust standards as we noted above for the ori-
ginal risk stratification analyses.
For trials that do not have adequate outcome predic-
tion tools to use, risk tools can often be developed on
pre-existing data in the trial planning phase, or prior to
analysis. Use of internally developed risk models has
been advocated [16,51,52] and several large trials have
used this approach as the basis for testing risk-based
HTE [53-55]. Future work should explore the degree to
which over-fitting may bias such an approach and, if so,
how best to avoid this. Regardless of the approach, in
most instances in which a risk-based analysis shows sig-
nificant HTE, the finding will be a call for rigorous fol-
low-up research to assess and optimize clinically-feasible
risk prediction.
Other medical conditions may have multiple models
that might yield clinically different results, frequently on
the individual patient-level (where clinical recommenda-
tions may be altered depending on which model is used)
and sometimes regarding the presence or absence of
HTE overall. While future work is needed to address
this issue, it should be noted that the ambiguity about
how best to treat individuals in such cases is revealed,
not created, by risk-based analysis.
This paper has focused exclusively on binary out-
comes. Continuous outcomes can be approached with
similar principles regarding testing for HTE, as well as
primary and secondary subgroup analyses, but obviously
metrics such as ARR and RRR would need to be
replaced by absolute and relative changes in the contin-
uous measure of interest; and NNT is not pertinent to
continuous outcomes, unless the continuous measures
are grouped into justifiable binary categories.
Additionally, we focused on heterogeneity in the
dimension of outcome risk; other risk dimensions may
also be important, such as the risk of treatment-related
harm (for therapies with serious and common adverse
events) [15] or competing risk (especially for conditions
including many patients with multiple morbidities or
older patients in trials measuring longer-term outcomes)
[8,56-58]. Multivariate models predicting treatment-
related adverse events, such as those developed to pre-
dict anticoagulant- or thrombolytic-related serious
bleeding [59,60] or surgical risks for specific procedures,
may be useful in the first case, and comorbidity indices
[56,61] in the second. There are also examples where
combining models for treatment-related harm with out-
come risk models to stratify trial results using a risk-
benefit scheme has yielded informative results [17,21].
However, whether, when, and how to perform these
complex analyses are methodologically fraught issues
that may be difficult to make routine recommendations
on.
As we and others have noted elsewhere, we will never
be able to get all the information needed for informing
clinical practice and health policy from experimental
trials [5,27-29,62,63]. The approach we outline here may
not be applicable or feasible for many trials, particularly
early phase trials, which tend to be small and explana-
tory in nature, and often use surrogate instead of clinical
endpoints. Furthermore, the above suggestions only deal
with assessing HTE statistically in the context of trials
and not how best to promote the use of risk stratifica-
tion in clinical practice. Despite these caveats and lim-
itations, for pivotal, phase III clinical trials using
clinically important outcomes, the suggested approach
should usually be feasible and should substantially
improve our ability to produce scientifically valid infor-
mation on HTE to better inform clinical practice.
Conclusion
Implications for the peer-review and publishing of
clinical trials
While it is well appreciated that outcome risk hetero-
geneity is common and can lead to clinically meaningful
HTE, few clinical trials analyze the variation in treat-
ment effect across the spectrum of patients in their stu-
dies and subgroup analyses are performed and reported
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nals should not dictate the scientific questions that
investigators address, for many important trials, the
results are not fully disclosed in the absence of a risk-
based analysis. While risk-stratified results may empha-
size the importance of treatment in high-risk patients
and may even result in the discovery of patient sub-
groups who benefit when summary results of trials are
negative, such analyses may be particularly resisted
when trial results are overall positive, given the obvious
incentives for industry to get treatments approved for as
broad a population as possible [14]. There also exist
incentives to selectively highlight positive exploratory
subgroup analyses, when overall results are negative.
Therefore, it seems likely that inadequate investigation
and reporting of HTE will continue to be a problem
unless editors, granting agencies and government regula-
tors insist upon it. Suggestions herein provide a frame-
work for the development of implementable guidelines
that might support routine examination and reporting
of information essential for optimizing medical care for
individuals.
Additional material
Additional file 1: Predictive models for some commonly used
outcomes in clinical trials; references for 95 prognostic models.
Competing interests
Dr Kent has received research funding from Pfizer, Inc.
Authors’ contributions
All authors contributed to the conceptual framework presented in the
manuscript. DMK and RAH co-wrote the initial draft. All authors revised the
manuscript for important content and approved the final manuscript.
Appendix
Appendix 1. Glossary
Baseline Risk
Risk of a particular event (in this paper, typically the primary study outcome)
in the absence of the experimental therapy.
Event rate
Proportion or percentage of study participants in a group in which a
particular event (typically the primary outcome) is observed. Control event
rate (CER) and experimental event rate (EER) are used to refer to event
rates in the control group and experimental group, respectively. In a clinical
trial, baseline risk is best estimated by the observed control event rate (CER).
Relative Risk Reduction (RRR)
The proportional reduction in the rate of bad events between experiment
(experimental event rate [EER]) and control (control event rate [CER]) patients
in a trial, calculated as (CER - EER)/CER. Moreover, we use the term “net RRR”
in this paper to emphasize that we are assessing the overall treatment benefit
(treatment-related benefit minus treatment-related harm). This is merely the
RRR when outcome measure is a composite of all major outcomes related to
the treatment, both those that are decreased and those that are increased by
treatment. For parsimony, we consider here that all outcomes have similar
importance, but this may not necessarily by generalizable (e.g. many
composite outcomes in the literature are a conglomerate of endpoints with
very different connotations and clinical importance).
Absolute Risk Reduction (ARR)
The absolute arithmetic difference in event rates between the control group
and the experimental group (CER - EER).
Number Needed to Treat (NNT)
The number of patients who need to be treated, on average, to prevent 1
additional bad outcome; calculated as 1/ARR.
Appendix 2. Checklist for Reporting on Subgroup Analyses & Heterogeneity
in Treatment Effects
1. Evaluate and report on the distribution of risk in the overall study
population and in the separate treatment arms of the study by using a
risk prediction model or index.
￿ Report on the distribution of predicted risk (or risk score) in the study
population overall and by treatment arm.
￿ Risk reporting should allow readers to assess the full distribution of the
study population either graphically (e.g., histograms or box & whiskers plots)
or by including information on the mean, standard deviation, median and
interquantile ranges.
2. Primary subgroup analyses should include reporting how relative and
absolute risk reduction varies in a risk-stratified analysis.
￿ The risk prediction model should be pre-specified (i.e., fully specified before
any analysis of treatment-effect has begun) and preferably externally
developed.
￿ Both absolute and relative risk reductions must be reported.
3. Any additional primary subgroup analysis should be pre-specified and
limited to patient attributes with strong a priori pathophysiological or
empirical justification.
￿ All primary subgroup comparisons must be pre-specified.
￿ Prespecification should include all aspects of the subgroup analysis,
including threshold values for continuous or ordinal variables where these
are used.
￿ All primary subgroup analyses must be justified based upon
pathophysiological or empirical evidence that this factor modifies treatment
effects.
4. Conduct and report on secondary (exploratory) subgroup analyses
separately from primary subgroup comparisons.
￿ Secondary subgroup analyses must be reported separately from primary
subgroup analyses and clearly labeled as exploratory (potential useful for
hypothesis generation and informing future research, but having little or no
immediate relevance to patient care).
5. All analyses conducted must be reported and statistical testing of HTE
should be done using appropriate methods (such as interaction terms)
and avoiding overinterpretation.
￿ Reporting must include results for all subgroup analyses conducted and
the paper must state that primary subgroup analyses conducted were pre-
specified and reported.
￿ Statistical comparisons should be limited to reporting for statistical
significance of treatment heterogeneity between subgroups using
interaction terms. (Testing for the significance of a treatment effect within a
subgroup is inappropriate due to poor statistical power).
￿ Statistical comparisons should be corrected for the number of primary
subgroup analyses performed.
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